Samuel Sia
Samuel Sia, a Professor of Biomedical Engineering at Columbia University, has developed novel technologies for point-of-care blood tests, both in an academic and industry setting. He is co-founder of Claros Diagnostics, whose prostate-cancer blood test for doctor’s offices has garnered FDA approval and is being commercialized by OPKO Health (NYSE: OPK). Sia’s work in global health diagnostics has garnered coverage from Nature, Science, JAMA, Washington Post, BBC, NPR and Voice of America. His lab-on-a-chip device has been tested in Rwanda to collect and analyze blood tests at a patient’s bedside to diagnose infectious diseases. He was named by MIT Technology Review as one of the world's top young innovators in 2010, and is an inducted fellow of the American Institute for Medical and Biological Engineering. Sia is also founder of Harlem Biospace, a biotech incubator facility in New York City (developed with the NYC mayor’s office) that has hosted over 50 biotech companies. He currently directs the entrepreneurship initiative for Columbia School of Engineering and Applied Sciences. Sia has a B.Sc. in Biochemistry from the University of Alberta, and a Ph.D. in Biophysics (with a HHMI predoctoral fellowship) from Harvard University. Sia completed a postdoctoral fellowship in Chemistry and Chemical Biology at Harvard University.
Biography current as of February 10, 2020